Transgenomic's Q4 Revenues Slide 22 Percent

Transgenomic's CEO said that its acquisition of Clinical Data's testing and biomarker development business in December will give the firm an additional $13 million in revenue annually while providing it "a much larger presence both with insurers and patients."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories